GSK raises $1.5B from sale of remaining Haleon stake

GSK has raised $1.52 billion from a sale of its remaining stake in consumer healthcare company Haleon, per a Reuters report, which noted that the sale will enable GSK to sharpen its attention on vaccines, cancer and infectious diseases. 

GSK sold around 385 million shares at 324 pence each, amounting to a 4.2% stake in Haleon. Friday's sale was at a discount of about 2.5% to Haleon's last close of 332.4 pence on Thursday, the report said.

[Read moe: Haleon selects Collectively as influencer, marketing partner]

Haleon, in which GSK initially owned nearly 13%, was spun out and listed on the London Stock Exchange in July 2022.

GSK said total proceeds from sales of its Haleon holdings—four in just over a year—stood at 3.9 billion pound, per the report. 

The company was the second-largest Haleon shareholder after Pfizer, which currently holds close to a 22.6% after selling a $3.5 billion stake in March. Pfizer remains Haleon's biggest shareholder.

[Read more: GSK’s proposed health spinoff to be named Haleon]